0.2, 0.3 or 0.4 mg moxonidine.

 

Treatment of hypertension.

 

Moxonidine is contraindicated in patients with: known hypersensitivity to any of the components of the product (see list of excipients), sick sinus syndrome or severe bradycardia (resting HR< 50 beat/minute).

 

If moxonidine is used in combination with a beta-blocker and both treatments have to be discontinued, the beta-blocker should be discontinued first and moxonidine only thereafter. Although accumulation does not occur, in patients with renal dysfunction (GFR less than 60 ml/min.), the hypotensive effect of moxonidine should be monitored carefully, especially at the beginning of the treatment. Treatment with moxonidine should not be discontinued abruptly.

 

Most frequent side effects reported include dry mouth, headache, dizziness, general weakness and sleepiness. These symptoms often decrease after the first few weeks of treatment. Less frequent side effects include nausea, difficulty sleeping and allergic reactions. Isolated cases of angioedema have been reported.

 

The usual initial dose of moxonidine is 0.2 mg daily, with a maximum daily dose of 0.6 mg given as two divided doses. The maximum single dose is 0.4 mg.

 

for PDF files, a free viewer is downloadable on the Adobe Systems' World Wide Website